Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT06166134
NCT06166134Not yet recruitingNot Applicable

Radiological Evaluation of Sarcopenia in Patient Received Chemotherapy

Assiut University0 sites72 target enrollmentStarted: January 2024Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Enrollment
72
Primary Endpoint
Radiological evaluation of sarcopenia in patients receiving chemotherapy
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Radiological evaluation of sarcopenia in patients receiving chemotherapy

Detailed Description

Evaluation of muscle mass by using sonoelastography and computed tomography

Study Design

Study Type
Observational
Observational Model
Other
Time Perspective
Cross Sectional

Eligibility Criteria

Ages
18 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •all cancer patients receiving chemotherapy referred to radiodiagnosis department for routine examination Patients must be between 18 and

Exclusion Criteria

  • •Previous or current history of any musculoskeletal or neurological disorder including strokes.
  • •Systemic atrophy affecting CNS ( Huntington disease ,hereditary ataxia ,spinal muscular disorder and related syndromes ,post polio syndrome )
  • •Central nervous system demyelinating disease ( Multiple sclerosis , acute disseminated demyelinated syndromes..
  • •Corticosteroids undertaken currently or for the past 3 years with doses >5mg/day.

Outcomes

Primary Outcomes

Radiological evaluation of sarcopenia in patients receiving chemotherapy

Time Frame: April 2025

Using sonoelastography and computed tomography in evaluation of muscle mass in patients received chemotherapy by measurement of muscle thickness ,echogencity ,cross sectional area ,fasicle length,pennation angle, strain ratio,shear wave velocity

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Doaa Maher

Resident doctor

Assiut University

Similar Trials

Active, not recruiting
Not Applicable
Evaluation of Pretreatment Sarcopenia in Patients With Inoperable High-grade Ovarian Carcinoma as Part of Optimised ManagementOvarian Carcinoma
NCT05415527Institut Bergonié25
Completed
Not Applicable
A study on sarcopenia induced by anti-cancer molecular targeted agentsmalignancies indicated for molecular targeted agents
JPRN-UMIN000019477Department of Clinical Oncology and Chemotherapy, Nagoya University Hospital29
Unknown
Not Applicable
The Role of the Muscle-nervous System Interface in Cancer CachexiaCachexia; Cancer; Sarcopenia
NCT03477721University of Roma La Sapienza40
Recruiting
Not Applicable
JUMP Prevalence of Sarcopenia and Chemobrain in Post-cancer PatientsSarcopeniaCancer
NCT05800535Hospices Civils de Lyon100
Active, not recruiting
Not Applicable
Association of weakness and low muscle mass with clinical outcomes in hemodialysis patients: SARC-HD projectSarcopenia
RBR-82p87rqCentro Universitário ICESP
Radiological Evaluation of Sarcopenia in... | Clinical Trial